AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04888455 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Quantitative sensory testing (QST)
Description: Demographic data, pain characteristics, health status, emotional well-being, personality and lifestyle are assessed by questionnaires. Additionally, all patients underwent a clinical neurological examination and quantitative sensory testing (QST) according to the German Research Network on Neuropathic Pain (DFNS).
Study NCT03214887 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RV-P1501
Description: Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
Study NCT03946202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen Peroxide
Description: Hydrogen Peroxide
Study NCT00591071 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional glycemic control
Description: Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
Study NCT02340780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buparlisib
Study NCT04070222 — intervention group
Intervention type: OTHER
Intervention: Hysteroscopy
Description: 1. Three groups of patients will be enrolled: Natural labour group, Cesarean scar group and Cesarean with diverticulum (PCSD) group;~2. Hysteroscopy will be carried out for uterine cavity examine and the specimen collection for further microflora analysis and inflammation marker detection;~3. ART will be carried out with standard protocol and the clinical outcome will be recorded;~4. The primary outcome of the study is the comparation of species and communities of uterine microflora and inflammatory markers of the female uterus among three groups. The secondary outcome is biochemical pregnancy rate, clinical pregnancy rate, embryo implantation rate and live birth rate.
Study NCT00841971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: 200 mg IV loading dose followed by 100 mg qd for 21 days
Study NCT00841971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: 400 mg IV for 21 days
Study NCT01883128 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI Targeted biopsies
Description: Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
Study NCT02005653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
Study NCT02005653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diethylcarbamazine
Description: Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
Study NCT02005653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: Experimental
Study NCT00975520 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Patients will be observed after surgery until recurrence when they will be offered radiation therapy
Study NCT00975520 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
Study NCT02365298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: etafilcon A
Description: etafilcon A soft contact lens
Study NCT02365298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: etafilcon A soft contact lens
Study NCT02365298 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nelfilcon A
Description: nelfilcon A
Study NCT02365298 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A
Description: nelfilcon A
Study NCT02213926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196 (acalabrutinib)
Study NCT04196972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication Intervention
Description: Receive ECHO telementoring intervention
Study NCT05767073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle InterVEntion (LIVE)
Description: The lifestyle intervention Coaching on Lifestyle (CooL) (van Rinsum 2018)),formed the basis of LIVE and was adapted to specific dysfunctional elements in depressed patients regarding motivation and self-management.~The focus is on reducing depressive symptoms, enhancing the quality of life and possibly achieving weight loss.~The lifestyle intervention lasts six months, with 13 weekly 1.5 to 2 hour group sessions and five 45 to 60 -minute individual sessions with at least one person from the patient's support network of friends or family (preferably sharing the same household). All sessions end with individual homework exercises, and each session starts with a 10 to 15-minute positive psychology intervention (PPI) and 5 to 15 minutes of physical activity. These sessions are followed by two booster sessions after about two and six months. Groups consist of 4-8 people.
Study NCT02729324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Radiation Protectants (FORRAD®)
Description: Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
Study NCT02729324 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trolamine (Biafine)
Description: Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
Study NCT00980278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift augmentation and dental implant
Description: transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
Study NCT00980278 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aastrom BRCs
Description: sinus augmentation, BRC application, dental implant
Study NCT00846781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denufosol tetrasodium Inhalation Solution
Description: 60 mg by oral inhalation three times daily
Study NCT01121874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligament reconstruction with suture fixation system
Description: CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
Study NCT01121874 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ligament Reconstruction with Tendon Interposition (LRTI)
Description: commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
Study NCT01121874 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ligament reconstruction with suture fixation system
Description: CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
Study NCT02463162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversations Matter videos
Description: 2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
Study NCT03127345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omegaven
Description: Intravenous omega 3 fatty acid administration
Study NCT03127345 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid
Description: Standard of care
Study NCT00478556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omnipaque
Description: Oral CT contrast
Study NCT00478556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastroview
Description: Oral CT contrast
Study NCT01716832 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Walking
Description: Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
Study NCT01941316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20/36 \* mg/m\^2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
Study NCT01941316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 125 mg/m\^2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
Study NCT02775435 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT02775435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT02775435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT02775435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT02775435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: IV infusion
Study NCT02775435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion Carboplatin dose should not to exceed 900 mg.
Study NCT02775435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: IV infusion Carboplatin dose should not to exceed 900 mg.
Study NCT02775435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline placebo for pembrolizumab
Description: IV infusion
Study NCT01872611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic Suspension, 0.3%
Study NCT01872611 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Inactive ingredients used as placebo comparator
Study NCT02842723 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Protontherapy
Description: 59,5 Gy (1,7 Gy daily, 5 fractions per week).
Study NCT01710670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Strength: 200 mg (4 x 50 mg)~Form: oral tablet~Frequency: single dose~Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1.
Study NCT01710670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Form: intravenous infusion~Frequency: continuous infusion~Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L.
Study NCT01710670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brivaracetam Placebo
Description: In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
Study NCT01710670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ethanol Placebo
Description: In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
Study NCT03480022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide Pen Injector [Saxenda]
Description: daily sc injection of liraglutide with final dose of 3mg daily
Study NCT03480022 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Liraglutide Pen Injector
Description: daily sc injection of placebo liraglutide with final dose of 3mg daily of placebo
Study NCT01346644 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Powder infant formula
Study NCT01346644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Powder infant formula
Study NCT02297230 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy (RT)
Description: Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
Study NCT02297230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
Study NCT02297230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
Study NCT02297230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
Study NCT04196972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04196972 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Waiting List
Description: Placed on wait-list
Study NCT02629484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Focused cardiac ultrasound
Description: focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
Study NCT01583920 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: focal salvage HDR prostate brachytherapy
Description: Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
Study NCT03701321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC
Study NCT03701321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Given SC
Study NCT03701321 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV
Study NCT03701321 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Daratumumab
Description: Given IV
Study NCT03701321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT02005653 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Experimental
Study NCT01044277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glutathione supplementation
Description: 500 mg, two times daily
Study NCT01044277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gluthathione peroxidases
Description: 125 mg, two times daily
Study NCT01044277 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 times daily
Study NCT02645305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adipose derived stem cells
Description: Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
Study NCT03370835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Non-cardioselective beta-blocker
Study NCT01872611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study NCT03370835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol
Description: Non-cardioselective beta-blocker
Study NCT01872611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone acetate
Description: 1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
Study NCT00589472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Given PO
Study NCT00589472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC
Study NCT04308447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AbleLite
Description: The AbleLite device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
Study NCT00589472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00589472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM
Study NCT00589472 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo radical prostatectomy
Study NCT00589472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Given PO
Study NCT03701321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Given PO
Study NCT03701321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study NCT03183011 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Description: Cardiac MRI
Study NCT01556737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High daidzein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones
Study NCT01556737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High daidzein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones
Study NCT01556737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High genistein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones
Study NCT01556737 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High genistein supplement
Description: 8 weeks exposure to the supplement, daily 100 mg of isoflavones